전립선특이항원(PSA) 검사 시장 규모 : 검사 유형별, 분석 유형별, 최종 사용자별, 지역별 및 예측별

Global Prostate-specific Antigen (PSA) Testing Market Size And Forecast

Market capitalization in the prostate-specific antigen (PSA) testing market reached a significant USD 3.5 Billion in 2025 and is projected to maintain a strong 8.9% CAGR during the forecast period from 2027 to 2033. A company-wide policy adopting predictive maintenance and digital twin integration runs as the strong main factor for great growth. The market is projected to reach a figure of USD 5.8 Billion by 2033, indicating a significant reassessment of the entire economic landscape.

Global Prostate-specific Antigen (PSA) Testing Market Overview

Prostate-specific antigen (PSA) testing is a diagnostic classification used to identify laboratory procedures designed to measure the concentration of prostate-specific antigen in blood samples for the purpose of detecting prostate-related abnormalities. The term functions as a clinical category that groups screening, monitoring, and risk-assessment tests used in urology and oncology practice. Boundaries of this category are determined through clinical guidelines, diagnostic methodology, and laboratory regulatory standards that define acceptable assay performance and reporting criteria.

In healthcare research and clinical diagnostics, PSA testing operates as a standardized reference point that supports consistent interpretation of prostate cancer screening data across hospitals, laboratories, and public health agencies. The classification helps maintain comparability in diagnostic reporting, clinical decision pathways, and long-term patient monitoring. Alignment of laboratory assay protocols and quality assurance procedures ensures that PSA testing remains a reliable measurement tool within routine urological assessment.

The PSA testing market is influenced by ongoing demand for early detection tools and disease monitoring practices within aging male populations. Clinical utilization is shaped less by rapid technological shifts and more by diagnostic reliability, physician practice patterns, and healthcare guideline alignment. Procurement decisions within laboratories and hospitals are influenced by assay accuracy, regulatory compliance, and integration with existing diagnostic platforms used in routine pathology workflows.

Global Prostate-specific Antigen (PSA) Testing Market Drivers

The market drivers for the prostate-specific antigen (PSA) testing market can be influenced by various factors. These may include:

Increasing Incidence of Prostate Cancer and Aging Male Population: The rising incidence of prostate cancer across aging male populations is strengthening demand for PSA testing procedures within clinical screening programs. Early diagnostic evaluation is receiving greater emphasis within oncology care pathways. According to the World Health Organization, more than 1.4 million new prostate cancer cases are reported globally each year, reinforcing regular screening adoption across hospitals and diagnostic laboratories.

Expansion of Preventive Health Screening Programs: The growing expansion of preventive health screening initiatives is increasing utilization of PSA testing across hospital networks and diagnostic laboratories. National health systems are integrating routine prostate cancer screening within male health check programs. Early detection strategies are strengthening clinical decision pathways. Diagnostic laboratories are expanding testing capacity to support increasing screening volumes across aging patient populations.

Advancement of Automated Immunoassay Diagnostic Platforms: Continuous advancement in automated immunoassay diagnostic platforms is supporting operational efficiency within PSA testing laboratories. High-throughput analyzers are improving laboratory productivity while maintaining consistent biomarker detection accuracy. Integration with laboratory information systems is streamlining patient reporting workflows. Hospitals and pathology labs are strengthening procurement of automated platforms to support expanding oncology screening demand.

Growing Awareness and Physician Recommendation for Early Cancer Detection: Increasing awareness regarding early prostate cancer detection is accelerating clinical adoption of PSA testing across primary healthcare settings. Physicians are incorporating biomarker screening within routine examinations for aging male patients. Educational campaigns within public health programs are improving patient participation in diagnostic screening. Early detection protocols are supporting structured oncology referral pathways across healthcare systems.

Global Prostate-specific Antigen (PSA) Testing Market Restraints

Several factors act as restraints or challenges for the prostate-specific antigen (PSA) testing market. These may include:

Concerns Regarding False Positive Results and Diagnostic Overdiagnosis: Concerns surrounding false positive PSA test results are limiting the wider acceptance of routine screening protocols across certain clinical guidelines. Elevated PSA levels may occur due to benign prostate conditions, introducing diagnostic uncertainty within early cancer detection pathways. Physicians are exercising caution in recommending widespread screening. Additional confirmatory testing requirements are increasing diagnostic complexity across healthcare providers.

Variability in Screening Recommendations Across Healthcare Authorities: Variability in prostate cancer screening guidelines across international health authorities is creating uncertainty within PSA testing adoption patterns. Divergent clinical recommendations regarding age thresholds and screening frequency are influencing physician decision frameworks. Healthcare systems are implementing localized diagnostic policies. This variation is moderating the pace of uniform screening adoption across hospital and diagnostic laboratory networks.

Limited Accessibility to Advanced Diagnostic Infrastructure in Developing Regions: Limited accessibility to advanced diagnostic laboratories and automated immunoassay systems is slowing PSA testing adoption across developing healthcare markets. Resource constraints are restricting the expansion of oncology screening programs within regional hospitals. Laboratory infrastructure upgrades are progressing gradually in several emerging healthcare systems. As a result, diagnostic coverage for prostate cancer screening remains uneven across global populations.

Clinical Debate Regarding Screening Effectiveness and Mortality Reduction: Ongoing clinical debate regarding the effectiveness of routine PSA screening is influencing diagnostic adoption across certain healthcare systems. The U.S. Preventive Services Task Force indicates that prostate cancer screening benefits vary across patient groups, while prostate cancer accounts for about 1 in 8 cancer diagnoses among men in the United States. Guideline variation is moderating universal screening implementation.

Global Prostate-specific Antigen (PSA) Testing Market Segmentation Analysis

The Global Prostate-specific Antigen (PSA) Testing Market is segmented based on Test Type, Essay Type, End-User, and Geography.

Prostate-specific Antigen (PSA) Testing Market, By Test Type

In the prostate-specific antigen (PSA) testing market, analysis is commonly segmented across four main test types. Total Prostate Specific Antigen (tPSA) is used as the initial screening tool to measure overall PSA levels in the blood. Free Prostate Specific Antigen (fPSA) is measured to help distinguish between benign conditions and cancer when tPSA levels are moderately elevated. The PSA RT-PCR Test is utilized for detecting specific genetic markers related to prostate cancer, often used for monitoring recurrence. The market dynamics for each test type are broken down as follows:

Total Prostate Specific Antigen (tPSA): tPSA maintains steady demand within the PSA testing market, as its role as the primary, first-line screening tool for prostate health supports consistent testing volume across diverse healthcare settings. Preference for an initial, broad assessment of prostate-related irregularities is witnessing increasing adoption in routine check-ups and urological evaluations, reinforcing its foundational position in the diagnostic algorithm.

Free Prostate Specific Antigen (fPSA): fPSA is witnessing substantial growth in the PSA testing market, driven by its critical application in resolving diagnostic ambiguity when tPSA levels fall within the borderline "grey zone." Expanding clinical guidelines recommending its use to reduce unnecessary biopsies is raising fPSA consumption.

PSA RT-PCR Test: The PSA RT-PCR Test is witnessing growing adoption, as molecular-level detection capabilities are enabling highly sensitive measurement of PSA-related genetic material, crucial for monitoring minimal residual disease and biochemical recurrence. Utilization in post-treatment surveillance for prostate cancer patients is witnessing increasing interest due to its ability to detect recurrence earlier than conventional immunoassays.

Prostate-specific Antigen (PSA) Testing Market, By Essay Type

In the prostate-specific antigen (PSA) testing market, analytical detection is performed across several immunoassay platforms. Enzyme Immunoassay (EIA) utilizes enzyme-labeled reagents for colorimetric detection, offering a non-radioactive alternative. Chemiluminescent Immunoassay (CLIA) employs chemiluminescent labels for highly sensitive and rapid automated analysis. Enzyme-Linked Immunosorbent Assay (ELISA) is a plate-based technique widely used for its robustness and ability to process multiple samples simultaneously in a research or clinical lab setting. The market dynamics for each assay type are broken down as follows:

Enzyme Immunoassay (EIA): EIA is witnessing steady utilization in the PSA testing market, particularly in laboratories with moderate throughput or in regions where cost sensitivity is a primary consideration for assay selection. Demand for a reliable, established technology that does not require expensive automated chemiluminescent readers is showing a sustained interest in EIA. Compatibility with standard laboratory equipment supports its continued use.

Chemiluminescent Immunoassay (CLIA): CLIA is dominating the PSA testing market, as its high sensitivity, wide dynamic range, and full automation capabilities are ideal for high-volume hospital and reference laboratory workflows. Demand for rapid turnaround times and reduced manual intervention is witnessing increasing adoption of CLIA platforms. Consistency in precision and throughput efficiency strengthens the CLIA segment's market share in modern diagnostics.

Enzyme-Linked Immunosorbent Assay (ELISA): ELISA is witnessing substantial growth within specific segments of the PSA testing market, driven by its utility in batch testing for epidemiological studies and research applications. Expanding research into novel PSA isoforms and biomarkers is raising the consumption of flexible ELISA kits. Its ease of use and ability to run multiple samples cost-effectively are showing a growing interest among academic and pharmaceutical research institutions.

Prostate-specific Antigen (PSA) Testing Market, By End-User

In the prostate-specific antigen (PSA) testing market, end-user demand is led by a mix of clinical and diagnostic facilities. Hospitals serve as primary centers for testing, often integrated with urology departments and inpatient care. Diagnostic centers specialize in high-throughput, standalone testing services for physicians and patients. Specialty clinics, such as urology practices, offer focused testing as part of comprehensive prostate health management. The market dynamics for each end-user are broken down as follows:

Hospitals: Hospitals are dominating the PSA testing market, as comprehensive patient care pathways, including screening, diagnosis, and treatment, are frequently consolidated within large medical centers. Increasing patient footfall and the presence of multidisciplinary urology and oncology teams are leading to the growing adoption of in-house automated testing systems. A preference for integrated electronic health records supports higher testing volumes within hospital networks.

Diagnostic Centers: Diagnostic centers are witnessing substantial growth within the PSA testing market, driven by anticipated demand from referring physicians and direct patient access for routine screening. Expansion of preventive health check packages is showing a growing interest in including PSA tests as a standard component. Cost-efficiency and the ability to aggregate samples for high-volume processing are encouraging the use of specialized diagnostic laboratories.

Specialty Clinics: Specialty clinics are experiencing steady expansion, as PSA testing is directly integrated into urology practice workflows for initial consultation and ongoing patient management. The rising prevalence of prostatic conditions is witnessing increasing adoption of point-of-care or near-patient testing solutions in these settings. Preference for immediate results to facilitate clinical decision-making drives procurement by specialty providers.

Prostate-specific Antigen (PSA) Testing Market, By Geography

In the prostate-specific antigen (PSA) testing market, North America and Europe show high demand tied to established screening guidelines, aging populations, and widespread health insurance coverage for preventive care. Asia Pacific leads in growth potential, driven by large populations, rising healthcare awareness, and expanding healthcare infrastructure in nations like China and India. Latin America remains a developing market with growth linked to improving access to urological care and diagnostic services. The Middle East and Africa rely on imports and developing public health systems, with demand linked to growing cancer awareness and the expansion of specialized hospital networks, making affordability and access key factors across the region. The market dynamics for each region are broken down as follows:

North America: North America dominates the PSA testing market, as strong demand from routine health screenings and urological follow-ups supports high consumption of testing kits and automated platforms. Advanced healthcare infrastructure and established reimbursement frameworks are witnessing increasing adoption of next-generation PSA assays. The presence of major diagnostic manufacturers and large reference laboratories, particularly in states like California, reinforces the regional market size.

Europe: Europe is witnessing substantial growth in the PSA testing market, driven by anticipated demand from organized cancer screening programs and national health service protocols in countries like Germany and France. Regulatory focus on standardized diagnostic quality and performance supports consistent use of validated immunoassays. Adoption of age-specific PSA reference ranges is showing a growing interest across urology practices.

Asia Pacific: Asia Pacific is witnessing the fastest expansion in the PSA testing market, as large and aging populations, particularly in China and India, are generating a rising volume of prostate health assessments. Rapidly improving healthcare infrastructure and expanding health insurance coverage are leading to the increasing adoption of modern diagnostic technologies. Rising domestic awareness of cancer screening is strengthening the regional market size.

Latin America: Latin America is experiencing steady growth, as expanding middle-class access to private healthcare and diagnostic services is increasing demand for PSA testing. Emerging urology and oncology centers in urban hubs like Sao Paulo, Brazil, are showing a growing interest in automated immunoassay analyzers. Infrastructure improvements and regional health ministry initiatives support gradual capacity utilization.

Middle East and Africa: The Middle East and Africa are witnessing gradual growth in the PSA testing market, as developing tertiary care hospitals and cancer treatment centers are driving selective demand for PSA diagnostics. Expansion of medical tourism and investment in healthcare infrastructure in the UAE and Saudi Arabia is witnessing increasing adoption of comprehensive laboratory services. Rising investment in public health awareness is strengthening long-term regional demand.

Key Players

• The competitive landscape is increasingly determined by how well players adjust to new consumer values, even though it is still based on brand equity and scale. Even though market consolidation continues to change the strategic map, supply chain ethics, scientific innovation in comfort, and verifiable eco-credentials are now the main areas of strategic differentiation.
• Key Players Operating in the Global Prostate-specific Antigen (PSA) Testing Market
• Abbott Laboratories
• Bayer AG
• Bio-Rad Laboratories, Inc.
• Beckman Coulter, Inc.
• Roche Diagnostics
• Siemens Healthineers
• DiaSorin S.p.A.
• Fujirebio
• GE HealthCare
• Laboratory Corporation of America Holdings (LabCorp)
• OPKO Health
• Ortho Clinical Diagnostics

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 MARKET DEFINITION
• 1.2 MARKET SEGMENTATION
• 1.3 RESEARCH TIMELINES
• 1.4 ASSUMPTIONS
• 1.5 LIMITATIONS

2 RESEARCH METHODOLOGY

• 2.1 DATA MINING
• 2.2 SECONDARY RESEARCH
• 2.3 PRIMARY RESEARCH
• 2.4 SUBJECT MATTER EXPERT ADVICE
• 2.5 QUALITY CHECK
• 2.6 FINAL REVIEW
• 2.7 DATA TRIANGULATION
• 2.8 BOTTOM-UP APPROACH
• 2.9 TOP-DOWN APPROACH
• 2.10 RESEARCH FLOW
• 2.11 DATA PRODUCT TEST TYPES

3 EXECUTIVE SUMMARY

• 3.1 GLOBAL PROSTATE-SPECIFIC ANTIGEN (PSA) TESTING MARKET OVERVIEW
• 3.2 GLOBAL PROSTATE-SPECIFIC ANTIGEN (PSA) TESTING MARKET ESTIMATES AND FORECAST (USD BILLION)
• 3.3 GLOBAL PROSTATE-SPECIFIC ANTIGEN (PSA) TESTING MARKET ECOLOGY MAPPING
• 3.4 COMPETITIVE ANALYSIS: FUNNEL DIAGRAM
• 3.5 GLOBAL PROSTATE-SPECIFIC ANTIGEN (PSA) TESTING MARKET OPPORTUNITY
• 3.6 GLOBAL PROSTATE-SPECIFIC ANTIGEN (PSA) TESTING MARKET ATTRACTIVENESS ANALYSIS, BY REGION
• 3.7 GLOBAL PROSTATE-SPECIFIC ANTIGEN (PSA) TESTING MARKET ATTRACTIVENESS ANALYSIS, BY TEST TYPE
• 3.8 GLOBAL PROSTATE-SPECIFIC ANTIGEN (PSA) TESTING MARKET ATTRACTIVENESS ANALYSIS, BY ESSAY TYPE
• 3.9 GLOBAL PROSTATE-SPECIFIC ANTIGEN (PSA) TESTING MARKET ATTRACTIVENESS ANALYSIS, BY END-USER
• 3.10 GLOBAL PROSTATE-SPECIFIC ANTIGEN (PSA) TESTING MARKET GEOGRAPHICAL ANALYSIS (CAGR %)
• 3.11 GLOBAL PROSTATE-SPECIFIC ANTIGEN (PSA) TESTING MARKET, BY TEST TYPE (USD BILLION)
• 3.12 GLOBAL PROSTATE-SPECIFIC ANTIGEN (PSA) TESTING MARKET, BY ESSAY TYPE (USD BILLION)
• 3.13 GLOBAL PROSTATE-SPECIFIC ANTIGEN (PSA) TESTING MARKET, BY END-USER (USD BILLION)
• 3.14 FUTURE MARKET OPPORTUNITIES

4 MARKET OUTLOOK

• 4.1 GLOBAL PROSTATE-SPECIFIC ANTIGEN (PSA) TESTING MARKET EVOLUTION
• 4.2 GLOBAL PROSTATE-SPECIFIC ANTIGEN (PSA) TESTING MARKET OUTLOOK
• 4.3 MARKET DRIVERS
• 4.4 MARKET RESTRAINTS
• 4.5 MARKET TRENDS
• 4.6 MARKET OPPORTUNITY
• 4.7 PORTER'S FIVE FORCES ANALYSIS
  • 4.7.1 THREAT OF NEW ENTRANTS
  • 4.7.2 BARGAINING POWER OF SUPPLIERS
  • 4.7.3 BARGAINING POWER OF BUYERS
  • 4.7.4 THREAT OF SUBSTITUTE PRODUCTS
  • 4.7.5 COMPETITIVE RIVALRY OF EXISTING COMPETITORS
• 4.8 VALUE CHAIN ANALYSIS
• 4.9 PRICING ANALYSIS
• 4.10 MACROECONOMIC ANALYSIS

5 MARKET, BY TEST TYPE

• 5.1 OVERVIEW
• 5.2 GLOBAL PROSTATE-SPECIFIC ANTIGEN (PSA) TESTING MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY TEST TYPE
• 5.3 TOTAL PROSTATE SPECIFIC ANTIGEN (TPSA)
• 5.4 FREE PROSTATE SPECIFIC ANTIGEN (FPSA)
• 5.5 PSA RT-PCR TEST

6 MARKET, BY ESSAY TYPE

• 6.1 OVERVIEW
• 6.2 GLOBAL PROSTATE-SPECIFIC ANTIGEN (PSA) TESTING MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY ESSAY TYPE
• 6.3 ENZYME IMMUNOASSAY (EIA)
• 6.4 CHEMILUMINESCENT IMMUNOASSAY (CLIA)
• 6.5 ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)

7 MARKET, BY END-USER

• 7.1 OVERVIEW
• 7.2 GLOBAL PROSTATE-SPECIFIC ANTIGEN (PSA) TESTING MARKET: BASIS POINT SHARE (BPS) ANALYSIS, BY END-USER
• 7.3 HOSPITALS
• 7.4 DIAGNOSTIC CENTERS
• 7.5 SPECIALTY CLINICS

8 MARKET, BY GEOGRAPHY

• 8.1 OVERVIEW
• 8.2 NORTH AMERICA
  • 8.2.1 U.S.
  • 8.2.2 CANADA
  • 8.2.3 MEXICO
• 8.3 EUROPE
  • 8.3.1 GERMANY
  • 8.3.2 U.K.
  • 8.3.3 FRANCE
  • 8.3.4 ITALY
  • 8.3.5 SPAIN
  • 8.3.6 REST OF EUROPE
• 8.4 ASIA PACIFIC
  • 8.4.1 CHINA
  • 8.4.2 JAPAN
  • 8.4.3 INDIA
  • 8.4.4 REST OF ASIA PACIFIC
• 8.5 LATIN AMERICA
  • 8.5.1 BRAZIL
  • 8.5.2 ARGENTINA
  • 8.5.3 REST OF LATIN AMERICA
• 8.6 MIDDLE EAST AND AFRICA
  • 8.6.1 UAE
  • 8.6.2 SAUDI ARABIA
  • 8.6.3 SOUTH AFRICA
  • 8.6.4 REST OF MIDDLE EAST AND AFRICA

9 COMPETITIVE LANDSCAPE

• 9.1 OVERVIEW
• 9.2 KEY DEVELOPMENT STRATEGIES
• 9.3 COMPANY REGIONAL FOOTPRINT
• 9.4 ACE MATRIX
  • 9.4.1 ACTIVE
  • 9.4.2 CUTTING EDGE
  • 9.4.3 EMERGING
  • 9.4.4 INNOVATORS

10 COMPANY PROFILES

• 10.1 OVERVIEW
• 10.2 ABBOTT LABORATORIES
• 10.3 BAYER AG
• 10.4 BIO-RAD LABORATORIES, INC.
• 10.5 BECKMAN COULTER, INC.
• 10.6 ROCHE DIAGNOSTICS
• 10.7 SIEMENS HEALTHINEERS
• 10.8 DIASORIN S.P.A.
• 10.9 FUJIREBIO
• 10.10 GE HEALTHCARE
• 10.11 LABORATORY CORPORATION OF AMERICA HOLDINGS (LABCORP)
• 10.12 OPKO HEALTH
• 10.13 ORTHO CLINICAL DIAGNOSTICS